Silver plans are exchange winners
Sixty-two percent of enrollees choose Silver plans
Today, the Department of Health and Human Services (HHS) announced that 3.3 million people have completed exchange enrollment through January, however, officials cannot say how many of the new sign ups have gone on to pay their initial premiums to health insurers.
In fourth quarter earnings reports, several national plans estimated their exchange enrollments:
Humana 200,000
WellPoint 500,000 on and off the exchanges
Aetna 135,000
Cigna 200,000 applications, with 20,000 paid enrollments
“Fifty-three percent more Americans are signed up today than were signed up by the end of December,” Kathleen Sebelius, HHS secretary, said in a press call. “In human terms, this means 1.16 additional Americans will have quality, affordable health coverage that’s there when they need it.”
HHS was able to drill down for the first time and report the sign ups by age and gender. In the federally facilitated and state exchanges, 25% of enrollees are between the ages of 18 and 34, and overall, 55% are women.
Likewise, the new report reveals plan selection by metal level. Because financial assistance is offered for Silver plans, they are the most popular, gaining 62% of enrollment.
Breaking Down Health Plans, HSAs, AI With Paul Fronstin of EBRI
November 19th 2024Featured in this latest episode of Tuning In to the C-Suite podcast is Paul Fronstin, director of health benefits research at EBRI, who shed light on the evolving landscape of health benefits with editors of Managed Healthcare Executive.
Listen
In this latest episode of Tuning In to the C-Suite podcast, Briana Contreras, an editor with MHE had the pleasure of meeting Loren McCaghy, director of consulting, health and consumer engagement and product insight at Accenture, to discuss the organization's latest report on U.S. consumers switching healthcare providers and insurance payers.
Listen
FDA Sets Goal Date for Lymphoma Drug Columvi
December 5th 2024The combination of Columvi, gemcitabine and oxaliplatin is the first CD20xCD3 bispecific antibody to show positive results in a randomized diffuse large B-cell lymphoma phase 3 trial. The FDA’s decision is expected by July 20, 2025.
Read More
